Why aren't MAOIs used more often?

Journal of Clinical Psychiatry

Volumn 70, Issue 1, 2009, Pages 139-140

  Fawcett, Jan ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; ISOCARBOXAZID; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SELEGILINE; THIORIDAZINE; THYROID HORMONE; TRANYLCYPROMINE;

ADD ON THERAPY; AGED; ANKLE EDEMA; BIPOLAR DEPRESSION; BORDERLINE STATE; CASE REPORT; DEPRESSION; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REMISSION; SEXUAL DYSFUNCTION; SHORT SURVEY; VAGUS NERVE STIMULATION;

CHRONIC DISEASE; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; DRUG RESISTANCE; ELECTROCONVULSIVE THERAPY; FOOD-DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; RISK FACTORS;

EID: 60349116313     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08ac04892     Document Type: Short Survey

References (2)

1. Sackheim HA. The definition and meaning of treatment resistant depression. J Clin Psychiatry 2001;62(suppl 16):10-17
2. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment refractory depression. J Clin Pharmacol 1991;11(2):127-132